When is micronized progesterone indicated, and what are its benefits, side effects, and contraindications?

Micronized Progesterone: Indications, Benefits, Side Effects, and Contraindications

Primary Indication

Micronized progesterone is indicated for endometrial protection in women with an intact uterus who are receiving estrogen therapy, whether for menopausal hormone therapy or premature ovarian insufficiency. 1

---

When Micronized Progesterone is Given

Menopausal Hormone Therapy

• Women with an intact uterus receiving estrogen therapy must receive concurrent progestogen to prevent endometrial hyperplasia and cancer 1, 2
• Dosing regimens include:
  • Sequential (cyclic): 200 mg daily for 10-14 days per month 1, 3
  • Continuous: 100 mg daily 1, 3
  • Alternative sequential: 100 mg daily for 12-14 days per month 3

Premature Ovarian Insufficiency

• Added 2-3 years after initiating estrogen therapy or when breakthrough bleeding occurs 4
• Continued until the average age of natural menopause (approximately 45-55 years) 3
• Dosing: 100-200 mg daily for 12-14 days every 28 days 4

Perimenopausal Irregular Cycles

• Luteal phase supplementation in perimenopausal patients with irregular menstrual cycles protects against endometrial hyperplasia and bleeding problems 1

High-Risk Women After Risk-Reducing Surgery

• In BRCA1/2 carriers under age 45 after risk-reducing salpingo-oophorectomy, micronized progesterone is preferred over synthetic progestins due to potentially lower breast cancer risk 5

---

Benefits

Endometrial Protection

• Provides complete endometrial protection when dosed at 200 mg daily for 12-14 days per month or 100 mg daily continuously 1, 3, 6
• Reduces risk of endometrial hyperplasia and cancer associated with unopposed estrogen 2, 7

Superior Safety Profile Compared to Synthetic Progestins

Cardiovascular advantages:

• Does not attenuate the vasodilating effects of estrogen 7, 6
• Neutral or beneficial effect on blood pressure 4, 8
• Lower risk of venous thromboembolism compared to synthetic progestins 4, 8
• No adverse effects on lipid profiles 1, 7

Breast cancer risk:

• Significantly lower breast cancer risk than synthetic progestins in observational studies 5, 6
• In BRCA carriers, limited data suggest micronized progesterone may be safer than synthetic progestins, though definitive evidence is lacking 5

Metabolic benefits:

• No androgenic activity 9
• Anti-mineralocorticoid effects 9
• Does not adversely affect insulin sensitivity or glucose tolerance 1

Neurological Benefits

• Acts as a neurosteroid with beneficial effects on anxiety, depression, and sleep when administered orally 8
• Improves working memory in peri- and menopausal women 8

---

Side Effects

Common Side Effects

• Mild, transient drowsiness is the most specific side effect 7, 6
• Dizziness may occur 8
• Premenstrual-tension-like symptoms including mood swings, bloating, fluid retention, and sleep disturbance (though less common than with synthetic progestins) 1

Management Strategies

• Administer at bedtime to minimize drowsiness 7
• Consider switching to vaginal administration if oral side effects are intolerable 1

Route-Specific Considerations

• Vaginal administration achieves adequate endometrial protection with fewer systemic side effects 1
• Vaginal formulations do not contain peanut oil, making them suitable for patients with peanut allergies 10

---

Contraindications

Absolute Contraindications (FDA-Labeled)

The following are absolute contraindications to micronized progesterone: 11

1. Known hypersensitivity to progesterone or its ingredients
2. Peanut allergy (oral micronized progesterone capsules contain peanut oil) 10, 11
3. Undiagnosed abnormal genital bleeding 11
4. Known, suspected, or history of breast cancer 11
5. Active deep vein thrombosis or pulmonary embolism, or history of these conditions 11
6. Active arterial thromboembolic disease (stroke, myocardial infarction) or history of these conditions 11
7. Known liver dysfunction or disease 11
8. Known or suspected pregnancy 11

Special Populations

Patients with peanut allergies:

• Use vaginal gel formulations instead of oral capsules, as they do not contain peanut oil 10

Patients with hormone receptor-positive breast cancer:

• Progesterone is contraindicated 10
• Non-hormonal alternatives should be considered for vasomotor symptoms 5

---

Clinical Pitfalls and Practical Considerations

Monitoring

• Do NOT use FSH levels to monitor adequacy of hormone replacement therapy 1, 3
• Monitor lipid profiles and cardiovascular risk factors 1

Compounded Preparations

• Avoid custom-compounded progesterone preparations lacking FDA oversight, as they have not demonstrated validated endometrial protection 3

Duration of Sequential Therapy

• Sequential progesterone must be administered for at least 10-12 days per month, with 12-14 days preferred for optimal endometrial protection 1, 3
• Long-cycle intermittent use (less than 10 days) raises concern for increased endometrial cancer risk 2

Maximum Dosing

• Do not exceed 200 mg daily in sequential regimens unless specific clinical indication exists 3
• This is the validated upper limit for endometrial protection 3

Route Selection Algorithm

1. First-line: Oral micronized progesterone 4, 3
2. If oral side effects are intolerable: Switch to vaginal administration 1
3. If peanut allergy: Use vaginal gel formulation 10
4. If venous thromboembolism risk: Consider transdermal estrogen with oral or vaginal progesterone 5

Pregnancy Considerations

• Women with premature ovarian insufficiency may spontaneously ovulate despite therapy 4
• Absence of withdrawal bleeding should prompt pregnancy testing in sequential regimens 4